Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.71 |
| ▸ | HPGD | P15428 | 5/20 | 0.71 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13166615 | 0.92 | KDM4E (0.73) | ALDH1A1KDM4EHSD17B10HPGDHTT | |
| SCHEMBL26491609 | 0.76 | KDM4E (0.72) | ALDH1A1KDM4EHSD17B10HPGDKMT2A | |
| SCHEMBL26491606 | 0.74 | KDM4E (0.69) | ALDH1A1KDM4EHSD17B10HPGDKMT2A | |
| SCHEMBL13261899 | 0.66 | ALDH1A1 (0.65) | ALDH1A1KDM4EHSD17B10HPGDHTT | |
| Prenyletin SCHEMBL30383964 | 0.65 | ALDH1A1 (1.00) | ALDH1A1KDM4EHSD17B10HPGDKMT2A | |
| Prenyletin SCHEMBL12062090 | 0.65 | ALDH1A1 (1.00) | ALDH1A1KDM4EHSD17B10HPGDKMT2A | |
| SCHEMBL31152138 | 0.65 | ALDH1A1 (0.83) | ALDH1A1KDM4EHSD17B10HPGDHTT | |
| SCHEMBL3775925 | 0.65 | ALDH1A1 (0.83) | ALDH1A1KDM4EHSD17B10HPGDHTT | |
| SCHEMBL6631881 | 0.65 | ALDH1A1 (0.49) | ALDH1A1KDM4EHSD17B10HPGDHTT | |
| SCHEMBL19354014 | 0.64 | KDM4E (0.52) | ALDH1A1KDM4EHSD17B10HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | BIOMARIN PHARMACEUTICAL INC. | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | ENGASE, GALNT1, GALNT13 | ALDH1A1 2125/4885KDM4E 3708/4885HSD17B10 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.